Daily MedNews
Printable Version   Email to a friend

Health Highlights: Aug. 27, 2008

Here are some of the latest health and medical news developments, compiled by editors of HealthDay:

Vaccine Said to Ward Off Bird Flu

An experimental bird flu vaccine appears to generate an immune response in people that can help guard against getting the disease, its producer says.

The deadly H5N1 strain of bird flu has killed more than 240 people since 2003, mostly in Asia. Experts worry that it will mutate to a form that's more easily passed from birds to people, triggering a human pandemic.

Novavax Inc. said of 160 people who got its two-injection vaccine, 94 percent produced an immune response against the virus, the Bloomberg news service reported.

The company's process uses insect-cell cultures, allowing it to produce seven to 10 times as much vaccine in the same span as older techniques that rely on mammal eggs or cells.

Traditional vaccines are made from chicken eggs, a process that can take up to six months. Novavax, by contrast, said it can produce a vaccine within 12 weeks of identifying a bird flu strain, Bloomberg reported.

-----

Parkinson's Drug Slows Disease Symptoms: Maker

A drug already approved by the U.S. Food and Drug Administration is the first medication to demonstrate that it hinders the progression of Parkinson's disease, the Bloomberg news service quotes the Israeli drug maker Teva Pharmaceuticals as saying.

Azilect slows the body's production of an enzyme that destroys dopamine, a hormone that when in short supply causes the tremors, depression, speaking and movement problems that characterize Parkinson's, the news service said.

In presenting clinical data at a medical conference in Madrid, Teva issued a statement saying Azilect demonstrated "significant improvement" in people who had taken the drug for 18 months, compared with those who had taken it for nine months.

Teva plans to ask the FDA for permission to label Azilect as a way to slow the progressive symptoms of Parkinson's, Bloomberg said.

-----

FDA Raises Concern About New Ovarian Cancer Test

The U.S. Food and Drug Administration says it is alarmed about a new blood test that its distributor says can detect ovarian cancer in its early stages, The New York Times reported Tuesday.

OvaSure, developed at Yale University, has been offered for about two months by one of the largest U.S. clinical laboratory firms, LabCorp. Despite an overwhelming need for such a test, the FDA and some medical organizations have raised red flags since its introduction in June, saying the diagnostic hasn't been tested enough, the Times said.

The Society for Gynecologic Oncologists almost immediately issued a statement, saying the organization feared unnecessary operations spurred by false positives.

If ovarian cancer is detected before it spreads from the ovaries, more than 90 percent of women in this stage will survive at least five years, the newspaper reported, citing the American Cancer Society.

Nonetheless, the FDA, which generally doesn't regulate diagnostics performed by a single laboratory, has informed LabCorp that there doesn't appear to be enough clinical data to validate that the test actually works, the Times reported.

In an Aug. 7 letter to LabCorp posted on the agency's Web site, the FDA said, "We believe you are offering a high-risk test that has not received adequate clinical validation and may harm the public health."

LabCorp responded that it looked forward to discussing the test with the agency, adding that it would continue to offer the diagnostic in the meantime, the newspaper said. The test costs $220 to $240.

The American Cancer Society estimates more than 21,000 cases of ovarian cancer will be diagnosed in the United States this year, and more than 15,000 are expected to die from the disease, the Times reported.

-----

Alabama to Charge Obese Workers Extra for Insurance

Any of Alabama's more than 35,000 state employees will be charged $25 per month for insurance that's usually free if they're too fat and don't work on losing the extra weight by January 2010, the Associated Press reported.

While other states reward workers who meet criteria for what's considered healthy, Alabama would be the first state to penalize those who qualify as obese. The monthly charge would apply to any state employee with a body mass index (BMI) of 35 or greater who "doesn't make progress" in slimming down, the wire service said. The state has yet to determine how much progress an employee would have to demonstrate.

A BMI of 30 or higher is considered obese. A person who is 5-feet, 6-inches tall and weighs 220 pounds would have a BMI of 35.5, the AP said.

The wire service cited statistics from the U.S. Centers for Disease Control and Prevention showing that Alabama ranks second in the nation behind Mississippi as the state with the biggest weight problem. Nearly one-third of Alabamians are obese.

The director of Alabama's State Employees' Insurance Board said that a person with a BMI of 35 to 39 faces about $1,750 more in medical expenses each year than a person with a BMI of less than 25.

Alabama already charges a premium to state workers who smoke.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 20, 2008
Audience: Consumers, endocrinological healthcare professionals [Posted 11/20/2008] Animas Corporation and FDA informed consumers...
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...